


(a)



				[LP(a)] (a)	
			apo(a)		LDL
					apob- 100
					APO(a)
			LP(a)		[]
				LP(a)	
				[]	
					apo(a)
LP(a)			LP(a)		
-				[]	
) / ± /			(
) / ± /			(
				[]	LP(a)
			LP(a)	LP(a)	
				[]	
				[]	
			LP(a)		
					[]
			(HDL-C), (LDL-C)		
			(APOB ,APOAI)		APO
		HDL-C LDL-C			LP(a)

³ Randox

¹ Low Density Lipoprotein

² High Density Lipoprotein

(LDL-C+HDL- VLDL-C []
 APOI , APOB ,LDL-C VLDL-C = C)
 LP(a) APOB ,APOAI ,LP(a)
 HDL-C (p< /)
 Cabas Mira
 BUN
 Pesce–Stande
 .[]

	Mean±SD	Mean±SD	
> /	/ ± /	/ ± /	()
> /	± /	/ ± /	(Kg/m ²) BMI ¹
< /	/ ± /	/ ± /	/
< /	± /	±	(g/l)
> /	/ ± /	/ ± /	(mg/dl)
> /	± /	± /	(mg/dl) BUN
< /	±	±	(mg/dl)
< /	±	±	(mg/dl)
> /	±	±	(mg/dl) HDL-C
< /	±	±	(mg/dl) LDL-C
< /	±	±	(mg/dl) APOAI
< /	±	±	(mg/dl) APOB
< /	± /	± /	(mg/dl) LP(a)

1. Body Mass Index

	p	r	p	r	
	< /	+ /	< /	/	
	< /	+ /	< /	/	
	< /	+ /	< /	/	LDL-C
	< /	/	< /	/	HDL-C
/	< /	+ /	< /	/	APOAI
	< /	/	< /	/	APOB
	< /	+ /	< /	/	LP(a)

()

LP(a) ()

[] APOB

APOAI APOB , LDL-C,

(p< /))

HDL-C (

[] (a)

LDL- , LP(a) , APOB

C

APOB

LDL

LP(a)

APOa

APO(a)

APO(a)

LP(a)

[]

ESRD

LP(a)

LP(a)

ESRD

LP(a)

LP(a)

[]

APOB

APOAI , LDL-C , LP(a)

APOB

ESRD

APOB

[]

LP(a)

LP(a)

[]

APOB APOAI , LDL-C ,

HDL-C LP(a)

LP(a)

²Noto

³Doucel

⁴Apolipoprotein(a)

¹End Stage Renal Disease

patients with glomerular proteinuria. *Nephrol Dial Transplant* . 1994; 9(3): 244-50.

7- Faucher C, Doucet C, Banmelon A, Chapman J, Jacobs C, Thillet J. Elevated lipoprotein (a) levels in primary nephrotic syndrome. *Am J Kidney Dis* . 1993 Dec; 22(6): 808-13 .

8- Stenvinkel P, Berglund L, Ericsson S, Alvestrand A, Angelin B, Eriksson M. Low density lipoprotein metabolism and its association to plasma lipoprotein(a) in the nephrotic syndrome. *Eur J Clin Invest* . 1997 Feb; 27(2): 169-77 .

9- Thiery J, Ivandic B, Bahlmann G, Walli AK, Seidol D. Hyperlipoproteinemia in nephrotic syndrome. *Eur J Clin Invest*. 1996 Apr; 26(4): 316 -21.

10- Stein EA, Myers GL. Lipids, lipoproteins and apolipoproteins . In: Burtin A, editor, *Tietz Textbook clinical chemistry*, 2nd ed. Philadelphia: W.B Saunders, 1994 : 1002-93.

11- Pesce MA, Strande CS. A new micromethod for the determination of protein in cerebrospinal fluid and urine . *Clin Chem*. 1973 Nov; 19(11): 1265-7.

12- Henry JB. *Clinical diagnosis and management by laboratory methods* , 19th ed. Philadelphia: W.B Sunders ,1996: 140-71.

13- Oida K, Takai H, Maeda H, Takahashi S, Shimada A, Suzuki J, et al. Apolipoprotein(a) is present in urine and its excretion is decreased in patients with renal failure. *Clin Chem*. 1992 Nov; 38(11): 2244-8.

14- Azrolan N, Brown CD, Thomas L, Hayek T, Zhao ZH, Roberts KG, et al. Cyclosporin A has divergent effects on plasma LDL, Cholesterol (LDL-C) and LP(a) levels in renal transplant recipients. Evidence for renal involvement in the maintenance of LDL-C and the elevation of LP(a) concentrations in hemodialysis patients. *Arterioscler*. 1994 Sep; 14(9): 1393-8.

15- Vega G, Toto RD, Grundy SM. Metabolism of low density lipoproteins in nephrotic dyslipidemia: Comparison of hypercholesterolemia alone and combined hyperlipidemia. *Kindney Int*. 1995 Feb; 47(2): 579-86.

16- Stenvinkel P, Berglund L, Ericsson S, Alvestrand A, Angelin B, Eriksson M. Low-density lipoprotein metabolism and its association to plasma lipoprotein(a) in the

[]

LP(a)

APOB

APOB

1- Jialal I. Evolving lipoprotein risk factors: lipoprotein (a) and oxidized low-density lipoprotein . *Clin Chem*. 1998 Aug; 44(8PT2): 1827-32 .

2- Brown MS, Goldstein JL. Teaching old dogmas new tricks. *Nature*. 1987Nov; 330(6144): 113-4.

3- Scanu AM, Fless GM. Lipoprotein(a). Heterogeneity and biological relevance. *J Clin Invest*. 1990 Jun; 85(6): 1709-15.

4- Hong SY, Yang DH. Lipoprotein(a) levels and fibrinolytic activity in patients with nephrotic syndrom. *Nephron* . 1995; 69(2): 125- 30.

5- Ordonez JD, Hiatt RA, Killebrew EJ, Fireman BH. The increased risk of coronary heart disease associated with nephrotic syndrome. *Kidney Int*. 1993 Sep; 44(3): 638-42.

6- Gansevoort RT, Heeg JE, Dikkeschei FD, de zeeuw D, De Jong PE, Dullaart RPF. Symptomatic antiproteinuric treatment decreases serum lipoprotein(a) concentration in

nephrotic syndrom. *Eur J Clin Invest.* 1997 Feb; 27(2): 159-77.

17- Kawasaki Y, Suzuk J, Nozawa R, Suzuki S, Suzuki H. Prediction of relapse by plasma lipoprotein(a) concentration in children with steroid sensitive nephrotic syndrom . *Nephrol.* 2002; 92(4): 807-11.

18- Thabet MA, Salcedo JR, Chan JC. Hyperlipidemia in childhood nephrotic syndrom. *Pediatr Nephrol.* 1993 Oct; 77(5): 559-66.

19- Noto D, Barbagallo CM, Cascio AL, Cefaln AB, Cavera G, Caldarell R, et al. Lipoprotein(a) levels in relation to albumin concentration in children nephrotic syndrome. *Kidney Int.* 1999; 55(6): 2433 -9.

20- Doucet C, Mooser V, Gonbert S, Raymond F, Chapman J, Jacobs C, et al. Lipoprotein(a) in the nephrotic syndrom: Molecular analysis of lipoprotein(a) and apolipoprotein(a) fragments in plasma and urine . *J AM Soc Nephrol.* 2000; 11(3): 507-13.

21- Nanner C, Rader D, Bartens W, Kramet J, Brewer HB, Schollmeyer P, et al. Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome. *Ann Intern Med.* 1993 Aug; 119(4): 263-9.

22- Mangeais C, Braschi S, Ouguerram P, Maugeais P, Mahot p, Jacotot B. Lipoprotein kinetics in patients with analbuminemia: Evidence for the role of serum albumin in controlling lipoprotein metabolism. *Arterioscler Thromb Vascbiol.* 1997 Jul; 17(77): 1369-75.

23- Stenvinkel P, Berglund L, Heimbürger D, Patterson E, Alvestrand A. Lipoprotein(a) in nephrotic syndrome. *Kindney Int.* 1993 Nov; 44(5): 1116-23.